Core Insights - Autolus Therapeutics reported a successful first year for AUCATZYL, achieving $74.3 million in revenue for 2025 and expanding its U.S. treatment-center network [2] Group 1: Commercial Launch and Financial Outlook - The company ended 2025 with 67 activated centers and aims to increase this to over 80 by the end of 2026 [3] - Autolus reiterated its 2026 net product revenue guidance of $120 million to $135 million and anticipates transitioning to positive gross margins in 2026 [3] - The expected gross margin improvement is attributed to higher volumes reducing fixed costs and operational improvements lowering variable costs per manufacturing batch [3] Group 2: Market Access and Revenue Contributions - The 2026 revenue guidance includes contributions from both the U.S. and U.K., but the company does not plan to specify the expected U.K. contribution, which is considered "substantially smaller" than that from the U.S. [4] - Autolus does not expect revenue contributions from other EU countries in 2026 and is in discussions with market access authorities to enter markets in an "economically sensible" manner [4] Group 3: Real-World Data and Patient Outcomes - The ROCCA consortium reported data on 96 patients authorized for treatment with obe-cel, with 91 receiving infusions; five patients did not receive infusions due to medical reasons [5] - For the analysis at the beginning of 2026, 84 patients were evaluable for a day 28 response assessment, with a median follow-up of 137 days from the first infusion, representing about 60% of U.S. commercial patients treated in the first year [6]

Financial Data and Key Metrics Changes - In 2025, Autolus recognized $74.3 million in revenue from AUCATZYL, with Q4 2025 net product revenue at $23.3 million [5][36] - The company expects net revenue for 2026 to be between $120 million and $135 million, with a shift to positive gross margins anticipated [5][46] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million for the same period in 2024 [39] Business Line Data and Key Metrics Changes - AUCATZYL's launch in the U.S. has been successful, with 67 centers activated by the end of 2025, and plans to increase to over 80 centers by the end of 2026 [5][6] - The company achieved regulatory approvals in the EU and U.K. by the end of 2025, initiating the launch in the U.K. at the beginning of 2026 [6] Market Data and Key Metrics Changes - The ROCCA consortium reported that 91 out of 96 patients treated with Obe-cel received infusions, with a 92% overall complete remission rate observed in the real-world setting [6][11] - The patient population treated showed a median age of about 50 years, with a wide range of age representation [8] Company Strategy and Development Direction - The company aims to broaden the utility of Obe-cel across additional indications, including pediatric patients and autoimmune diseases [14][15] - Autolus is focusing on expanding its commercial footprint and improving operational efficiencies to drive down costs and enhance gross margins [5][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial launch of AUCATZYL and the positive feedback from physicians [5] - The company is evaluating market access in Europe and is cautious about entering markets in a financially sustainable manner [54] Other Important Information - The company recorded a $1 million license revenue component in Q4 2025 related to a clinical milestone with Moderna [36] - Cash equivalents and marketable securities totaled $300.7 million at the end of 2025, down from $588 million at the end of 2024 [39][45] Q&A Session Summary Question: Guidance for 2026 revenue from U.K. and other regions - Management indicated that the 2026 guidance includes both U.S. and U.K. markets but will not break out specific contributions due to early launch stages [52][53] Question: Insights on LUMINA enrollment - Enrollment for the LUMINA study is gaining momentum, with U.S. centers expected to come online soon [63] Question: Impact of ROCKA results on physician behavior - Management believes the ROCKA data will help build confidence among physicians, which is crucial for market share growth [58][60] Question: Early data disclosure for ongoing studies - Management stated that they do not plan to disclose early data from ongoing studies like BOBCAT and LUMINA to maintain the integrity of the trials [72][76] Question: Evolution of gross margin post-positive shift - Management explained that increasing patient volume and optimizing the operating model will drive down production costs and improve gross margins [86][88]

Financial Data and Key Metrics Changes - In 2025, the company recognized $74.3 million in revenue from AUCATZYL, with a net product revenue of $23.3 million for Q4 2025 [5][34] - The total revenue for Q4 2025, including a $1 million license revenue component, was $24.3 million [35] - Cost of sales for Q4 2025 was $25.3 million, significantly higher than $11.4 million in Q4 2024, primarily due to a full quarter of sales and increased manufacturing expenses [36] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million in Q4 2024 [38] Business Line Data and Key Metrics Changes - The company achieved regulatory approvals in the EU and the U.K. by the end of 2025, initiating the launch of AUCATZYL in the U.K. at the beginning of 2026 [6] - The ROCCA consortium reported that 91 out of 96 patients treated with obe-cel received infusions, with a 92% overall complete remission rate observed in the real-world setting [11][12] Market Data and Key Metrics Changes - The company is targeting more than 80 activated centers by the end of 2026, building on the 67 centers activated by the end of 2025 [5] - The company does not expect significant contributions from the U.K. or other EU countries in 2026, focusing instead on the U.S. market [52][53] Company Strategy and Development Direction - The company aims to broaden the utility of AUCATZYL across additional indications, including pediatric patients and autoimmune diseases [15][17] - The focus for 2026 includes driving market share for AUCATZYL, improving gross margins, and expanding clinical trial programs [48] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for 2026, expecting net revenue of $120 million to $135 million and a shift to positive gross margins [5][43] - The company is evaluating market access strategies in Europe to ensure economically sensible entry [53] Other Important Information - The company has a strong foundation in the adult ALL segment and is actively pursuing additional studies, including the CATULUS study for pediatric patients and the LUMINA study for lupus nephritis [14][30] - The company expects to have sufficient cash equivalents and marketable securities to fund operations into Q4 2027 [44] Q&A Session Summary Question: Guidance for 2026 revenue from U.K. and other regions - Management indicated that the guidance includes both U.S. and U.K. markets but will not break out specific contributions due to early launch stages [51][52] Question: Insights on ROCCA results and physician behavior - Management expressed confidence that the ROCCA data will enhance physician confidence and experience, which is crucial for market share growth [57][60] Question: Enrollment progress in the LUMINA study - Management reported that enrollment is gaining momentum, with U.S. centers expected to come online soon [62] Question: Revenue recognition for patients receiving only one dose - Management clarified that revenue recognition will depend on whether patients receive a second dose, with specific factors influencing the timing [63][64] Question: Potential for early data disclosure from ongoing studies - Management stated that they do not plan to disclose early data from studies like BOBCAT and LUMINA to maintain the integrity of the trials [71][73]

Financial Data and Key Metrics Changes - In 2025, the company recognized $74.3 million in revenue from AUCATZYL, with a net product revenue of $23.3 million for Q4 2025 [4][34] - The total revenue for Q4 2025, including a $1 million license revenue component, was $24.3 million [34] - Cost of sales for Q4 2025 was $25.3 million, significantly higher than $11.4 million in Q4 2024, primarily due to a full quarter of sales and increased manufacturing expenses [34][37] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million in Q4 2024 [39] Business Line Data and Key Metrics Changes - The company achieved regulatory approvals in the EU and the U.K. by the end of 2025, initiating the launch of AUCATZYL in the U.K. at the beginning of 2026 [5][4] - The company is targeting over 80 activated centers by the end of 2026, building on the 67 centers activated by the end of 2025 [4] Market Data and Key Metrics Changes - The company does not expect significant contributions from the U.K. or other EU countries in 2026, as it is still early in the launch process [55] - The company is in discussions with market access authorities in Europe to evaluate appropriate paths for market entry [55] Company Strategy and Development Direction - The company aims to drive market share for Obe-cel, improve gross margins, and expand the utility of Obe-cel through ongoing clinical trial programs [50] - The company is focusing on broadening the product's indications, including pediatric patients and autoimmune diseases [13][14] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for 2026, expecting net revenue of $120 million to $135 million and a shift to positive gross margins [4][45] - The company anticipates that current cash equivalents and marketable securities will fund operations into Q4 2027 [45] Other Important Information - The company is conducting several studies, including the CATULUS study for pediatric patients and the LUMINA study for lupus nephritis, with pivotal data expected in 2027 and 2028 respectively [17][48] Q&A Session Summary Question: What is the expected contribution from the U.K. and other regions for the 2026 guidance? - The company does not plan to break out revenue contributions from the U.K. or other EU countries, as it is early in the launch process [54] Question: How is the LUMINA enrollment progressing? - The LUMINA study is gaining momentum, with U.S. centers expected to come online soon [63] Question: What are the expectations for gross margin evolution once it turns positive? - The company aims to drive down production costs through increased volume and operational optimization [86] Question: Will there be early data disclosures from ongoing studies? - The company does not plan to release early data from pivotal studies to maintain the integrity of the trials [75][76]

Core Insights - Autolus Therapeutics reported strong operational and financial results for the fourth quarter and full year ended December 31, 2025, highlighting the successful launch of AUCATZYL in the US and its market-leading position in treating adult patients with relapsed or refractory B-ALL [1][2] Financial Performance - AUCATZYL generated net product revenue of $23.3 million for Q4 2025 and $74.3 million for the full year 2025, primarily driven by US sales [5][6] - The company expects AUCATZYL net product revenue for 2026 to be between $120 million and $135 million, with a shift to positive gross margin anticipated [5][9] - The net loss for Q4 2025 was $90.3 million, compared to a net loss of $27.6 million for the same period in 2024, with a basic and diluted net loss per share of $(0.34) [18][20] Product and Pipeline Updates - AUCATZYL launched in the UK in January 2026 following a successful NICE evaluation, and real-world data from the ROCCA consortium confirmed its high clinical activity and favorable safety profile [5][6] - The company is focusing on expanding the utility of obe-cel in additional indications, including pivotal studies for pediatric r/r B-ALL and severe lupus nephritis [3][12] - Initial clinical data from the BOBCAT Phase 1 trial in progressive MS is expected by the end of 2026, with further updates on other trials planned for 2027 and 2028 [3][12][13] Operational Updates - Autolus initiated a manufacturing life cycle plan aimed at cost reductions and gross margin improvements, focusing on optimizing the current manufacturing model and enhancing automation [8] - The company reported an increase in research and development expenses to $35.6 million for Q4 2025, driven by clinical trial costs [16] Market Position and Future Outlook - The company aims to drive adoption of AUCATZYL in the US and expand its market presence in the UK, leveraging established commercial and manufacturing capabilities [2][3] - Autolus anticipates that increasing patient numbers in 2026 will improve manufacturing plant utilization and operational efficiencies, contributing to a positive gross margin shift [9]

Core Viewpoint - Autolus Therapeutics plc is set to release its fourth quarter and full year 2025 financial results and operational highlights on March 27, 2026, before the U.S. market opens [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for 8:30am EDT / 12:30pm GMT on the same day [2] - Participants are required to pre-register to receive dial-in numbers and a personal PIN for accessing the conference call [2] Group 2: Company Overview - Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies [3] - Autolus has a marketed therapy named AUCATZYL and a pipeline of candidates aimed at treating hematological malignancies, solid tumors, and autoimmune diseases [3]

Core Insights - Autolus Therapeutics has appointed Ryan Richardson to its Board of Directors, bringing over 20 years of experience in strategy and corporate development within the healthcare and investment banking sectors [1][4]. Group 1: Company Growth and Strategy - Autolus is entering a new growth phase as a commercial-stage company, with a focus on expanding the reach of its product obe-cel in new indications [2]. - The company is well-positioned with strong clinical data and proven CAR T manufacturing expertise, which supports its growth in current and future indications [3]. Group 2: Ryan Richardson's Background - Prior to joining Autolus, Mr. Richardson served as Chief Strategy Officer at BioNTech, where he played a key role in the company's global expansion and transition to a commercial stage [4]. - Mr. Richardson has extensive experience in strategic transactions, having worked as an Executive Director in J.P. Morgan's Global Healthcare Investment Banking team [4]. Group 3: Company Overview - Autolus Therapeutics is focused on developing next-generation T cell therapies for cancer and autoimmune diseases, utilizing proprietary T cell programming technologies [6]. - The company has a marketed therapy, AUCATZYL, and a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [6].

Core Insights - Autolus Therapeutics plc is positioning itself as a leader in CAR-T therapies, with a focus on expanding its product line and market reach [1][2][4] Group 1: Financial Performance - The company generated $21.1 million in product revenue in Q3, primarily from its CAR-T therapy AUCATZYL [1] - Autolus reported $51 million in sales from its flagship product Ocatzel for adult acute lymphoblastic leukemia (ALL) in the first nine months of the year [2] Group 2: Product Development and Market Expansion - Plans are in place to explore the use of Ocatzel in Pediatric ALL and autoimmune diseases to broaden its market target [3] - The company aims to increase physician adoption and patient awareness to enhance market share over the next two years [3] - Autolus has established an end-to-end infrastructure to improve production and supply capabilities in the UK and the US [3]

Core Insights - Autolus Therapeutics plc is participating in the Jefferies Global Healthcare Conference in London, with CEO Dr. Christian Itin scheduled to present on November 18, 2025 [1]. Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases [3]. - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies aimed at effectively recognizing and eliminating target cells [3]. - Autolus has a marketed therapy named AUCATZYL and is developing a pipeline of product candidates for hematological malignancies, solid tumors, and autoimmune diseases [3]. Event Details - A webcast of the fireside chat will be available on the company's website, with a replay archived for 90 days post-presentation [2].

Financial Data and Key Metrics Changes - In Q3 2025, net product revenue was $21.1 million, slightly up from $20.9 million in Q2 2025 [29] - Deferred revenue at the end of Q3 was $7.6 million, compared to $2.1 million in Q2 2025, indicating a healthy backlog of products ready for infusion [29] - The net loss for Q3 2025 was $79.1 million, reduced from a loss of $82.1 million in Q3 2024 [31] Business Line Data and Key Metrics Changes - AUCATZYL achieved $21.1 million in net sales for Q3 2025, with total sales of $51 million for the first nine months of the year [8][29] - The manufacturing success rate exceeded 90%, and patient access was achieved for over 90% of U.S. covered lives [9] Market Data and Key Metrics Changes - The CAR-T market share for the treatment of relapsed refractory B-ALL was approximately 15% before AUCATZYL's commercialization, increasing to around 20% within the 60 treatment centers currently active [10] Company Strategy and Development Direction - The company aims to drive market share in adult ALL, improve margins, and expand beyond ALL into pediatric ALL and other indications [8][33] - The focus is on optimizing operations and leveraging investments in infrastructure to enhance efficiencies [7][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial launch of AUCATZYL, highlighting positive feedback from physicians and the potential for growth in the CAR-T market [5][10] - The company is preparing for upcoming data presentations at ASH and expects to initiate pivotal studies in lupus nephritis and pediatric ALL [33] Other Important Information - The company has made key leadership changes to strengthen its operational capabilities, including the appointment of a new Chief Technology Officer and Chief Commercial Officer [12][13] Q&A Session Summary Question: Can you talk about the patient flow and anticipated patient flow going forward? - Management noted a good proportion of patients were not initially considered for CAR-T therapy, indicating an expansion of market penetration [35][37] Question: What is the competitive positioning for obe-cel in pediatric patients? - The focus is on high-risk pediatric patients who currently have limited options, with a strong safety and efficacy profile for obe-cel [39][41] Question: Can you provide insights on the Q3 performance and expectations for Q4? - Management indicated that Q3 performance was impacted by CMS reimbursement policy changes, but they expect a healthy amount of deferred revenue for Q4 [46][50] Question: What are the growth opportunities in the CAR-T market? - The majority of patients are not yet receiving CAR-T therapy, presenting significant growth opportunities within existing treatment centers [58][60] Question: What data is expected at ASH? - Key data points will include pediatric ALL study results and expanded data from the CARLYSLE study, focusing on safety and efficacy [68][70]